These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9590465)

  • 1. Evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study.
    Blum R; Schwartzel E; Siskin S; Epinette WW
    J Clin Pharmacol; 1998 Apr; 38(4):368-72. PubMed ID: 9590465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group.
    Highton A; Quell J
    J Am Acad Dermatol; 1995 Jan; 32(1):67-72. PubMed ID: 7822519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.
    Guzzo C; Lazarus G; Goffe BS; Katz HI; Lowe NJ; Pincus SH
    J Am Acad Dermatol; 1996 Mar; 34(3):429-33. PubMed ID: 8609254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.
    Bruce S; Epinette WW; Funicella T; Ison A; Jones EL; Loss R; McPhee ME; Whitmore C
    J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):755-9. PubMed ID: 7929921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp.
    Feldman SR; Mills M; Brundage T; Eastman WJ
    J Drugs Dermatol; 2013 Mar; 12(3):300-6. PubMed ID: 23545912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study.
    Pariser DM; Pariser RJ; Breneman D; Lebwohl M; Kalb R; Moore J; Moss H; Parker C; Fiedler V
    Arch Dermatol; 1996 Dec; 132(12):1527. PubMed ID: 8961897
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions.
    Kang S; Yi S; Griffiths CE; Fancher L; Hamilton TA; Choi JH
    Br J Dermatol; 1998 Jan; 138(1):77-83. PubMed ID: 9536226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis.
    Tirado-Sánchez A; Ponce-Olivera RM
    Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.
    White S; Vender R; Thaçi D; Haverkamp C; Naeyaert JM; Foster R; Martinez Escribano JA; Cambazard F; Bibby A
    Am J Clin Dermatol; 2006; 7(3):177-84. PubMed ID: 16734505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
    Fleming C; Ganslandt C; Leese GP
    J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
    Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
    J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
    Lebwohl M; Yoles A; Lombardi K; Lou W
    J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group.
    Cullen SI
    South Med J; 1996 Nov; 89(11):1053-6. PubMed ID: 8903286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
    Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
    J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcipotriene for psoriasis.
    Med Lett Drugs Ther; 1994 Aug; 36(928):70-1. PubMed ID: 8035754
    [No Abstract]   [Full Text] [Related]  

  • 19. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
    Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
    J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis.
    van de Kerkhof PC; Berth-Jones J; Griffiths CE; Harrison PV; Hönigsmann H; Marks R; Roelandts R; Schöpf E; Trompke C
    Br J Dermatol; 2002 Mar; 146(3):414-22. PubMed ID: 11952541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.